Drug intelligence / Profile preview

T330-ADC

Development stage: Preclinical
Lead developer: Nanolattix Biological
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

T330-ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Nanolattix. It is designed for the treatment of various solid tumors, including lung cancer, pancreatic cancer, and cervical cancer. The therapeutic candidate consists of a monoclonal antibody conjugated to a cytotoxic payload, a design intended to provide targeted delivery of the drug to malignant cells while reducing systemic side effects. As of early 2024, the program remains in the preclinical phase of development.

Beyond the preview

Go deeper on T330-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T330-ADC.

Explore the full profile